Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

646
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
646
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

245
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
245
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

702
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
702
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

320
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
320
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.2K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.2K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

305
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
305

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk-based pathology reporting after endoscopic submucosal dissection for early gastrointestinal cancer: international consensus standards.

Gut·2026
Same author

Detection of high-grade dysplasia and adenocarcinoma in Barrett's esophagus using high-resolution virtual chromoendoscopy versus the Seattle protocol: the CONVERSE study.

BMC gastroenterology·2026
Same author

Safety and efficacy of extended surveillance intervals following colorectal endoscopic submucosal dissection: an international multicentre study.

Gut·2026
Same author

Pre-liver transplant assessment of patients with acute-on-chronic liver failure: An international survey.

JHEP reports : innovation in hepatology·2026
Same author

Inter and intra-observer agreement for the LST Classification in Large (>2cm) Colorectal Laterally Spreading Tumours.

The American journal of gastroenterology·2026
Same author

Impact of knife size and saline-optimized electrosurgical modes on tissue effects in saline-immersion third-space endoscopy.

Scientific reports·2026

Related Experiment Video

Updated: Mar 8, 2026

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.6K

Liver Illness and Psychiatric Patients.

Paul Carrier1, Marilyne Debette-Gratien1, Murielle Girard2

  • 1Service D'hépato-Gastroentérologie, CHU Limoges, 87042 Limoges Cédex, France; INSERM, U850, F-87000 Limoges, Univ Limoges, France.

Hepatitis Monthly
|January 27, 2017
PubMed
Summary

Patients with psychiatric disorders face higher risks of liver disease, including hepatitis and non-alcoholic steato-hepatitis (NASH). Certain psychiatric medications can cause drug-induced liver injury (DILI), necessitating careful monitoring and treatment selection.

Keywords:
HepatotoxicityMental DisordersNon-Alcoholic Fatty Liver DiseaseViral Hepatitis

More Related Videos

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

8.0K
Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
06:52

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders

Published on: April 28, 2023

2.1K

Related Experiment Videos

Last Updated: Mar 8, 2026

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.6K
Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

8.0K
Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
06:52

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders

Published on: April 28, 2023

2.1K

Area of Science:

  • Psychiatry
  • Hepatology
  • Clinical Pharmacology

Background:

  • Patients with psychiatric disorders exhibit increased comorbidity with somatic illnesses, particularly liver diseases.
  • Established links exist between psychiatric conditions and various hepatitis types (viral, alcoholic), especially in substance abusers.
  • Metabolic syndrome, steatosis, and non-alcoholic steato-hepatitis (NASH) are prevalent in individuals with chronic psychiatric disorders undergoing psychotropic treatment.

Purpose of the Study:

  • To highlight the increased prevalence of liver diseases in psychiatric patients.
  • To underscore the association between psychotropic medications and drug-induced liver injury (DILI).
  • To emphasize the need for screening and careful management of liver health in this population.

Main Methods:

  • Review of existing literature on psychiatric disorders and liver disease.
  • Analysis of the impact of psychotropic medications on liver function.
  • Evaluation of screening protocols for liver conditions in psychiatric patients.

Main Results:

  • Psychiatric patients are disproportionately affected by liver conditions like hepatitis and NASH.
  • Specific psychiatric medications (neuroleptics, mood stabilizers, antidepressants) are linked to drug-induced liver injury (DILI).
  • Advanced liver disease may contraindicate certain psychiatric treatments, and psychiatric status can impact liver transplant eligibility.

Conclusions:

  • Close monitoring for liver disease is crucial in psychiatric patients, especially those on psychotropic drugs.
  • Screening for metabolic syndrome and NASH should be routine.
  • Careful consideration of medication interactions and patient history is vital for managing liver health in psychiatric populations.